<DOC>
	<DOCNO>NCT00416624</DOCNO>
	<brief_summary>RATIONALE : Epoetin alfa darbepoetin alfa may cause body make red blood cell . They use treat anemia cause chemotherapy patient cancer . PURPOSE : This randomized clinical trial study four different schedule epoetin alfa darbepoetin alfa compare well work treat patient anemia cause chemotherapy .</brief_summary>
	<brief_title>Epoetin Alfa Darbepoetin Alfa Treating Patients With Anemia Caused Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare relative efficacy four different erythropoietic agent dose schedule comprise epoetin alfa darbepoetin alfa , term proportion patient chemotherapy-associated anemia achieve weekly overall hematopoietic response . Secondary - Compare effect regimens mean hemoglobin increment measure weekly baseline 15 week patient baseline hemoglobin less equal 10.5 g/dL . - Compare time require achieve hemoglobin level within goal range 11.0-12.0 g/dL patient treat regimen . - Compare effect regimens proportion patient require red blood cell transfusion number transfusion require . - Compare weekly change hemoglobin patient treat regimen . - Compare need dose reduction patient treat regimen . - Compare adverse event profile regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , unblinded , pilot study . Patients stratify accord severity anemia ( mild [ hemoglobin ≥ 9.5 g/dL ] v severe [ hemoglobin &lt; 9.5 g/dL ] ) , platinum-containing regimen ( yes v ) , tumor type ( nonmyeloid hematologic malignancy v solid tumor ) . Patients randomize 1 4 treatment arm . - Arm I : Patients receive epoetin alfa subcutaneously ( SC ) day 1 . Treatment repeat weekly 15 course absence disease progression unacceptable toxicity . - Arm II : Patients receive epoetin alfa SC day 1 ( high dose arm I ) . Treatment repeat every 3 week 5 course absence disease progression unacceptable toxicity . - Arm III : Patients receive epoetin alfa SC day 1 ( high dose arm II ) . Treatment repeat every 3 week 5 course absence disease progression unacceptable toxicity . - Arm IV : Patients receive darbepoetin alfa SC day 1 . Treatment repeat every 3 week 5 course absence disease progression unacceptable toxicity . Hemoglobin level monitor throughout study weekly basis drug dose administer . Drug dose adjust ( e.g. , hold , reduce , resume low dose ) need maintain hemoglobin value within desire range . Quality life assess baseline week 4 , 7 , 10 , 13 , 16 . After completion study treatment , patient follow 30 day . PROJECTED ACCRUAL : A total 320 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis solid tumor nonmyeloid hematologic malignancy ( e.g. , plasma cell dyscrasia lymphoproliferative disorder ) No nonmelanomatous skin cancer Hemoglobin ≤ 10.5 g/dL Ferritin &gt; 20 ng/mL ( i.e. , obviously iron deficient ) Planning receive ≥ 12 week anticancer chemotherapy Biological therapy ( e.g. , hypomethylating agent , monoclonal antibody , small molecule pathway inhibitor ) individual cumulative regimen incidence grade 3 4 anemia &gt; 10 % consider chemotherapy purpose study No know anemia secondary following : Cyanocobalamin ( vitamin B_12 ) folic acid deficiency Gastrointestinal bleeding within past 2 week Hemolysis Myelodysplastic syndrome , myeloproliferative disorder , acute myeloid leukemia No primary hematologic disorder cause chronic moderate severe anemia ( e.g. , congenital dyserythropoietic anemia , homozygous hemoglobin S disease compound heterozygous sickling state , thalassemia major ) Carriers disease state allow provided anemic prior cancer diagnosis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 6 month Not pregnant nursing No delivery baby ≥ 18 week estimate gestational age within past 3 month ( 90 day ) Negative pregnancy test Fertile patient must use effective contraception Weight &gt; 40.0 kg &lt; 150.0 kg No known hypersensitivity epoetin alfa , darbepoetin alfa , mammaliancell derive product , human albumin No uncontrolled hypertension , define systolic blood pressure ( BP ) ≥ 180 mm Hg and/or diastolic BP ≥ 100 mm Hg , despite medical therapy No pulmonary emboli and/or deep vein thrombosis within past 12 month Patients actively receive warfarin minimum 4 week exempt requirement Prior superficial thrombophlebitis allow No cerebrovascular accident , ischemic stroke , acute coronary syndrome ( e.g. , unstable angina Qwave nonQ wave myocardial infarction ) , arterial venous thrombotic event within past 6 month No history chronic hypercoagulable disorder ( e.g. , activate protein C resistance , anticardiolipin disorder , protein C deficiency , protein S deficiency ) Patients receive anticoagulation therapy ( warfarin acetylsalicyclic acid [ aspirin ] dose ≥ 325 mg/day ) condition eligible provide therapy continue study period History previously treat seizure allow provided patient seizurefree minimum 3 month PRIOR CONCURRENT THERAPY : See Disease Characteristics More 1 year since prior peripheral blood stem cell , bone marrow , cord blood transplantation More 14 day since prior red blood cell transfusion More 14 day since prior major surgery , include , limited , follow : Amputation Invasion body cavity central nervous system use scalpel , saw , laser cut tool Resection body part ( part ) , whether solid liquid tissue , include ≥ 1 % patient 's preoperative weight The following consider major surgery : Diagnostic/therapeutic thoracentesis paracentesis Diagnostic skin biopsy Digit fingernail/thumbnail resection laceration repair local anesthesia Diagnostic fat aspiration Otic irrigation remove cerumen impaction Tympanocentesis Uncomplicated dental extraction Uncomplicated tonsillectomy Laser corneal remodel refraction purpose Cosmetic therapeutic eyelid surgery Bone marrow aspiration biopsy More 10 week since prior darbepoetin alfa , epoetin alfa , investigational form erythropoietin ( e.g. , geneactivated erythropoietin novel erythropoiesis stimulate protein ) No planned stem cell transplantation within next 4 month ( 18 week )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>anemia</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>mast cell leukemia</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
</DOC>